Skip to content
10-K

Annual Report

Urovant Sciences Ltd.

0001564590-20-029968

← back to feed
Filed
Jun 19, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2020 · Jun 18, 2020 30.8M sh
Operating Cash Flow FY 2020 · Mar 31, 2020 −$102.08M
Operating Cash Flow FY 2020 · Mar 31, 2019 −$109.04M
Cash And Equivalents FY 2020 · Mar 31, 2020 $51.41M
Cash And Equivalents FY 2020 · Mar 31, 2019 $85.35M
Stockholders Equity FY 2020 · Mar 31, 2020 −$58.01M
Stockholders Equity FY 2020 · Mar 31, 2019 $74.77M
Stockholders Equity FY 2020 · Mar 31, 2018 $7.07M
Current Liabilities FY 2020 · Mar 31, 2020 $30.93M
Current Liabilities FY 2020 · Mar 31, 2019 $11.82M
Total Liabilities FY 2020 · Mar 31, 2020 $121.3M
Total Liabilities FY 2020 · Mar 31, 2019 $25.35M
Current Assets FY 2020 · Mar 31, 2020 $58.32M
Current Assets FY 2020 · Mar 31, 2019 $98.51M
Total Assets FY 2020 · Mar 31, 2020 $63.3M
Total Assets FY 2020 · Mar 31, 2019 $100.12M
Sga Expense FY 2020 · Mar 31, 2020 $46.3M
Sga Expense FY 2020 · Mar 31, 2019 $18.59M
Rd Expense FY 2020 · Mar 31, 2020 $92.44M
Rd Expense FY 2020 · Mar 31, 2019 $92.2M
Net Income FY 2020 · Mar 31, 2020 −$146.75M
Net Income FY 2020 · Mar 31, 2019 −$111.35M
Long Term Debt FY 2020 · Mar 31, 2019 $13.53M